


1634  
JFW

Patent Application  
Attorney Docket No. PC11028A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22317-1450 on this 14th day of July, 2004.

By

  
(Signature of person mailing)  
Tracy Mycroft

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: L. Kathryn Durham, et al. :

APPLICATION NO.: 10/032,241 : Examiner: S. A. Sakelaris

FILING DATE: 12/21/01 : Group Art Unit: 1634

TITLE: Methods, Compositions and Kits Relating to :  
Cardiovascular Disease

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Pursuant to the duty of disclosure set forth in 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. § 1.97 and § 1.98, Applicant(s) hereby bring to the Examiner's attention the enclosed PTO-FB-A820 and the listed documents, copies of which are also enclosed.


The Examiner is requested to consider the cited documents and to indicate such consideration by returning a signed and initialed copy of the PTO-FB-A820 Form with the next communication from the Patent Office. Further, it is requested that the cited documents be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 to cover the cost of this submission in accordance with 37 C.F.R. 1.17(p). The Commissioner is further authorized to charge any additional fees, which may be required under 37 C.F.R. 1.16 and 1.17, or credit any overpayment, to Account No. 16-1445.

Should there be any questions regarding the above or the present application, the Examiner is invited to contact the undersigned at the below-listed number.

Date: July 14, 2004

Respectfully submitted,



---

Gabriel L. Kleiman  
Attorney for Applicant(s)  
Reg. No. 40,681

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-0041



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC11028A	SERIAL NO. 10/032,241
	APPLICANT L. Kathryn Durham et al.	
	FILING DATE 12/21/01	GROUP 1634

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

### FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Konno et al., GenBank Accession # BB138415, June 28, 2000
		Birren et al., GenBank Accession # AC020769, March 26, 2000
		The DOE Joint Genome Institute, GenBank Accession #AC010550, Sept 4, 2000
		Yamashita et al., Biochim Biophys Acta, 1529, 257-275, Dec 15, 2000

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.